At the beginning of the year Incyte paid $750m to Morphosys for the CD-19 targeting antibody, which has been approved in combination with BMS’ Revlimid (lenalidomide) for adults with relapsed or ...

CD ComputaBio announces today a groundbreaking computational platform that accelerates the design of Antibody-Drug Conjugates (ADCs) and significantly decreases the timelines and costs associated with ...